About context therapeutics inc - CNTX
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CNTX At a Glance
Context Therapeutics, Inc.
2001 Market Street
Philadelphia, Pennsylvania 19103
| Phone | 1-267-225-7416 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -36,123,615.00 | |
| Sector | Health Technology | Employees | 15 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CNTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.233 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.871 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
CNTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,408,241.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CNTX Liquidity
| Current Ratio | 8.498 |
| Quick Ratio | 8.498 |
| Cash Ratio | 8.229 |
CNTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -43.36 |
| Return on Equity | -46.39 |
| Return on Total Capital | -59.624 |
| Return on Invested Capital | -46.356 |
CNTX Capital Structure
| Total Debt to Total Equity | 0.185 |
| Total Debt to Total Capital | 0.185 |
| Total Debt to Total Assets | 0.164 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |